FR 186054
Latest Information Update: 18 Jul 2002
Price :
$50 *
At a glance
- Originator Fujisawa
- Class Antihyperlipidaemics
- Mechanism of Action Sterol O-acyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hyperlipidaemia
Most Recent Events
- 22 Oct 1998 New profile
- 22 Oct 1998 Preclinical development for Hyperlipidaemia in Japan (Unknown route)